SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-23-000145
Filing Date
2023-11-07
Accepted
2023-11-07 16:04:28
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20231107.htm   iXBRL 8-K 31562
5 EX-99.1 ex991pressreleaseq32023.htm EX-99.1 99039
6 denali_txlogox02a.jpg GRAPHIC 604226
  Complete submission text file 0001714899-23-000145.txt   1094768

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20231107.xsd EX-101.SCH 1934
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20231107_lab.xml EX-101.LAB 23834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20231107_pre.xml EX-101.PRE 12530
8 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20231107_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 231383611
SIC: 2836 Biological Products, (No Diagnostic Substances)